# US 2020/0399626 A1 · Uses of adenosine base editors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399626 A1
- Document ID: US20200399626A1
- Status: Published application
- Kind: A1
- Application number: 16/756,432
- Filed: 2018-10-16
- Published: 2020-12-24
- Earliest claimed: 2018-10-16
- Assignees: The Broad Institute, Inc.; President and Fellows of Flarvard College; Beam Therapeutics Inc.
- Applicants: The Broad Institute, Inc.; Beam Therapeutics, Inc.; President and Fellows of Flarvard College
- Inventors: David R. Liu; Nicole Gaudelli; Michael S. Packer; Gregory Newby
- Web page: https://patentgrep.com/patent/US20200399626A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Y 305/04004: Adenosine deaminase (3.5.4.4)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure provides methods and compositions for treating blood diseases/disorders, such as sickle cell disease, hemochromatosis, hemophilia, and beta-thalassemia. For example the disclosure provides therapeutic guide RNAs that target the promotor of HBG1/2 to generate point mutations that increase expression of fetal hemoglobin. As another example, the disclosure provides therapeutic guide RNAs that target mutations in HBB, Factor VIII, and HFE to treat sickle cell disease, beta-thalassemia, hemophilia and hemochromatosis. The disclosure also provides fusion proteins comprising a Cas9 (e.g., a Cas9 nickase) domain and adenosine deaminases that deaminate adenosine in DNA. In some embodiments, the fusion proteins are in complex with nucleic acids, such as guide RNAs (gRNAs), which target the fusion proteins to a DNA sequence (e.g., an HBG1 or HBG2 protmoter sequence, or an HFE, GBB, or F8 gene sequence). Such complexes may be useful for increasing expression of fetal hemoglobin or correcting a poing mutation (e.g., C282Y) in HFE.

## Claims

### Claim 1

A method for deaminating an adenosine (A) nucleobase in a sense or antisense strand of a promoter of an HBG1 or HBG2 gene, the method comprising contacting the promoter with a base editor and a guide RNA bound to the base editor, wherein the guide RNA (gRNA) comprises a guide sequence that is complementary to a target nucleic acid sequence in the promoter of at least one of the HBG1 and HBG2 gene.

### Claim at position 2

-3. (canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the target nucleic acid sequence comprises:
(SEQ ID NO: 838)
5′-CTTGGGGGCCCCTTCCCCACACTA-3′;
(SEQ ID NO: 839)
5′-CTTGGGGGCCCCTTCCCCACACT-3′;
(SEQ ID NO: 840)
5′-CTTGGGGGCCCCTTCCCCACAC-3′;
(SEQ ID NO: 841)
5′-CTTGGGGGCCCCTTCCCCACA-3′;
(SEQ ID NO: 842)
5′-CTTGGGGGCCCCTTCCCCAC-3′;
(SEQ ID NO: 843)
5′-CTTGGGGGCCCCTTCCCCA-3′;
(SEQ ID NO: 844)
5′-CTTGGGGGCCCCTTCCCC-3′;
[[or]]
(SEQ ID NO: 845)
5′-CTTGGGGGCCCCTTCCC-3′;
(SEQ ID NO: 297)
5′-CCACACTATCTCAATGCAAATATCTGTC-3′;
(SEQ ID NO: 298)
5′-CCACACTATCTCAATGCAAATATCTGT-3′;
(SEQ ID NO: 299)
5′-CCACACTATCTCAATGCAAATATCTG-3′;
(SEQ ID NO: 300)
5′-CCACACTATCTCAATGCAAATATCT-3′;
(SEQ ID NO: 301)
5′-CCACACTATCTCAATGCAAATATC-3′;
(SEQ ID NO: 302)
5′-CCACACTATCTCAATGCAAATAT-3′;
(SEQ ID NO: 303)
5′-CCGTTTCAGACAGATATTTGCAT-3′;
(SEQ ID NO: 304)
5′-CCAGGGACCGTTTCAGACAGATATTTGC-3′;
(SEQ ID NO: 305)
5′-CCAGGGACCGTTTCAGACAGATATTTG-3′;
(SEQ ID NO: 306)
5′-CCAGGGACCGTTTCAGACAGATATTT-3′;
(SEQ ID NO: 307)
5′-CCAGGGACCGTTTCAGACAGATATT-3′;
(SEQ ID NO: 308)
5′-CCAGGGACCGTTTCAGACAGATAT-3′;
(SEQ ID NO: 309)
5′-CCAGGGACCGTTTCAGACAGATA-3′;
(SEQ ID NO: 310)
5′-ACACTATCTCAATGCAAATATCT-3′;
(SEQ ID NO: 311)
5′-ACTATCTCAATGCAAATATCTGT-3′;
(SEQ ID NO: 312)
5′-CCTCTTGGGGGCCCCTTCCCCAC-3′;
(SEQ ID NO: 313)
5′-CCTTGTCAAGGCTATTGGTCAAG-3′;
(SEQ ID NO: 314)
5′-CCTTGCCTTGACCAATAGCCTTGACAAG-3′;
(SEQ ID NO: 315)
5′-CCTTGCCTTGACCAATAGCCTTGACAA-3′;
(SEQ ID NO: 316)
5′-CCTTGCCTTGACCAATAGCCTTGACA-3′;
(SEQ ID NO: 317)
5′-CCTTGCCTTGACCAATAGCCTTGAC-3′;
(SEQ ID NO: 318)
5′-CCTTGCCTTGACCAATAGCCTTGA-3′;
(SEQ ID NO: 319)
5′-CCTTGCCTTGACCAATAGCCTTG-3′;
(SEQ ID NO: 320)
5′-GCCTTGACCAATAGCCTTGACAA-3′;
(SEQ ID NO: 321)
5′-CCTTGACCAATAGCCTTGACAAG-3′;
(SEQ ID NO: 322)
5′-GCCTTGTCAAGGCTATTGGTCAA-3′;
or
(SEQ ID NO: 323)
5′-TCAAGTTTGCCTTGTCAAGGCTA-3′.

### Claim at position 4

-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the guide sequence comprises:
(SEQ ID NO: 846)
5′-UCAUGUGGGGAAGGGGCCCCCAAG-3′;
(SEQ ID NO: 847)
5′-CAUGUGGGGAAGGGGCCCCCAAG-3′;
(SEQ ID NO: 848)
5′-AUGUGGGGAAGGGGCCCCCAAG-3′;
(SEQ ID NO: 849)
5′-UGUGGGGAAGGGGCCCCCAAG-3′.
(SEQ ID NO: 850)
5′-GUGGGGAAGGGGCCCCCAAG-3′;
(SEQ ID NO: 851)
5′-UGGGGAAGGGGCCCCCAAG-3′;
(SEQ ID NO: 852)
5′-GGGGAAGGGGCCCCCAAG-3′;
or
(SEQ ID NO: 853)
5′-GGGAAGGGGCCCCCAAG-3′.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the target nucleic acid sequence comprises:
(SEQ ID NO: 838)
5′-CTTGGGGGCCCCTTCCCCACACTA-3′;
(SEQ ID NO: 839)
5′-CTTGGGGGCCCCTTCCCCACACT-3′;
(SEQ ID NO: 840)
5′-CTTGGGGGCCCCTTCCCCACAC-3′;
(SEQ ID NO: 841)
5′-CTTGGGGGCCCCTTCCCCACA-3′;
(SEQ ID NO: 842)
5′-CTTGGGGGCCCCTTCCCCAC-3′;
(SEQ ID NO: 843)
5′-CTTGGGGGCCCCTTCCCCA-3′;
(SEQ ID NO: 844)
5′-CTTGGGGGCCCCTTCCCC-3′;
or
(SEQ ID NO: 845)
5′-CTTGGGGGCCCCTTCCC-3′;
and
wherein deamination of the A nucleobase that is complementary to the T at position 14 of SEQ ID NO: 845 results in a T to C mutation in the target nucleic acid sequence.

### Claim 10 (depends on 1)

The method of claim 1, wherein the guide sequence comprises:
(SEQ ID NO: 254)
5′-GACAGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 255)
5′-ACAGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 256)
5′-CAGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 257)
5′-AGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 258)
5′-GAUAUUUGCAUUGAGAUAGUGUGG-3′;
[[or]]
(SEQ ID NO: 259)
5′-AUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 260)
5′-AUGCAAAUAUCUGUCUGAAACGG-3′;
(SEQ ID NO: 261)
5′-GCAAAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 262)
5′-CAAAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 263)
5′-AAAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 264)
5′-AAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 265)
5′-AUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 266)
5′-UAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 267)
5′-AGAUAUUUGCAUUGAGAUAGUGU-3′;
(SEQ ID NO: 268)
5′-ACAGAUAUUUGCAUUGAGAUAGU-3′;
(SEQ ID NO: 269)
5′-GUGGGGAAGGGGCCCCCAAGAGG-3′;
(SEQ ID NO: 270)
5′-CUUGACCAAUAGCCUUGACAAGG-3′;
(SEQ ID NO: 271)
5′-CUUGUCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 272)
5′-UUGUCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 273)
5′-UGUCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 274)
5′-GUCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 275)
5′-UCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 276)
5′-CAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 277)
5′-UUGUCAAGGCUAUUGGUCAAGGC-3′;
(SEQ ID NO: 278)
5′-CUUGUCAAGGCUAUUGGUCAAGG-3′;
(SEQ ID NO: 279)
5′-UUGACCAAUAGCCUUGACAAGGC-3′;
(SEQ ID NO: 280)
5′-UAGCCUUGACAAGGCAAACUUGA-3′;
(SEQ ID NO: 281)
5′-UUCUCCACAGGAGUCAGAUGCAC-3′;
(SEQ ID NO: 282)
5′-UCUCCACAGGAGUCAGAUGCACC-3′;
(SEQ ID NO: 283)
5′-UUCUCCACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 284)
5′-UCUCCACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 285)
5′-CUCCACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 286)
5′-UCCACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 287)
5′-CCACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 288)
5′-CACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 289)
5′-ACUUCUCCACAGGAGUCAGAUGC-3′;
(SEQ ID NO: 290)
5′-UCUCCACAGGAGUCAGAUGCACCAUGGU-3′;
or
(SEQ ID NO: 291)
5′-ACUCCUAAGGAGAAGUCUGCCGU-3′.

### Claim 11 (depends on 10)

The method of claim 10, wherein the target nucleic acid sequence comprises
(SEQ ID NO: 297)
5′-CCACACTATCTCAATGCAAATATCTGTC-3′;
(SEQ ID NO: 298)
5′-CCACACTATCTCAATGCAAATATCTGT-3′;
(SEQ ID NO: 299)
5′-CCACACTATCTCAATGCAAATATCTG-3′;
(SEQ ID NO: 300)
5′-CCACACTATCTCAATGCAAATATCT-3′;
(SEQ ID NO: 301)
5′-CCACACTATCTCAATGCAAATATC-3′;
or
(SEQ ID NO: 302)
5′-CCACACTATCTCAATGCAAATAT-3′
and wherein deamination of the A nucleobase that is complementary to the T at position 21 of SEQ ID NO: 302 results in a T to C mutation in the target nucleic acid sequence.

### Claim 12 (depends on 10)

The method of claim 10, further comprising deaminating a second A nucleobase in the sense or antisense strand of the promoter using a second gRNA comprising a second guide sequence that is complementary to a second target nucleic acid sequence wherein:
(a) the second target nucleic acid sequence comprises SEQ ID NO: 845;
(b) the second guide sequence comprises SEQ ID NO: 853; or
(c) both (a) and (b).

### Claim at position 11

-27. (canceled)

### Claim 28 (depends on 1)

The method of claim 1, wherein the guide sequence of the gRNA comprises:
(SEQ ID NO: 270)
5′-CUUGACCAAUAGCCUUGACAAGG-3′.

### Claim 29 (depends on 28)

The method of claim 28, wherein the target nucleic acid sequence comprises 5′-CCTTGTCAAGGCTATTGGTCAAG-3′ (SEQ ID NO: 313);
wherein deamination of an A nucleobase that is complementary to the T at any one of positions 15, 16, or 19 of SEQ ID NO: 313 results in a T to C mutation in the target nucleic acid sequence.

### Claim 30 (depends on 28)

The method of claim 28, further comprising deaminating a second A nucleobase in the sense or antisense strand of the promoter using a second gRNA comprising a second guide sequence that is complementary to a second target nucleic acid sequence wherein:
(a) the second target nucleic acid sequence comprises SEQ ID NO: 845, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 309, SEQ ID NO: 311, or SEQ ID NO: 312;
(b) the second guide sequence comprises SEQ ID NO: 853, SEQ ID NO: 259, SEQ ID NO: 260, or SEQ ID NO: 266, SEQ ID NO: 268, or SEQ ID NO: 269; or
(c) both (a) and (b).

### Claim at position 15

-41. (canceled)

### Claim 42 (depends on 1)

The method of claim 1, further comprising deaminating a second A nucleobase in the sense or antisense strand of the promoter using a second gRNA comprising a second guide sequence that is complementary to a second target nucleic acid sequence wherein:
(a) the second target nucleic acid sequence comprises SEQ ID NO: 845, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 309, SEQ ID NO: 311, SEQ ID NO: 312, SEQ ID NO: 313, SEQ ID NO: 319, SEQ ID NO: 320, or SEQ ID NO: 321;
(b) the second guide sequence comprises SEQ ID NO: 853, SEQ ID NO: 259, SEQ ID NO: 260, or SEQ ID NO: 266, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 276, SEQ ID NO: 277, or SEQ ID NO: 278; or
(c) both (a) and (b).

### Claim at position 17

-45. (canceled)

### Claim 46 (depends on 1)

The method of claim 1, wherein the step of contacting the promoter results in a T-A base pair in the promoter being mutated to a C-G base pair in the promoter.

### Claim 47

(canceled)

### Claim 48 (depends on 1)

The method of claim 1, wherein the step of contacting the promoter leads to an increase in transcription of the HBG1 gene or the HBG2 gene.

### Claim at position 21

-58. (canceled)

### Claim 59 (depends on 1)

The method of claim 1, wherein the method is performed in a cell of a subject who has a disease or disorder of the blood.

### Claim at position 23

-63. (canceled)

### Claim 64 (depends on 59)

The method of claim 59, wherein the disease or disorder is caused by a mutation in a gene, or a promoter of a gene, selected from CYGB, HBA1, HBA2, HBB, HBD, HBE1, HBG1, HBG2, HBM, HBQ1, HBZ, and MB.

### Claim 65

A method for deaminating an adenosine (A) nucleobase in a sense or antisense strand of an HFE gene, the method comprising contacting the HFE gene with a base editor and a guide RNA bound to the base editor, wherein the guide RNA comprises a guide sequence that is complementary to a target nucleic acid sequence in the HFE gene.

### Claim at position 26

-92. (canceled)

### Claim 93

A method for deaminating an adenosine (A) nucleobase in a sense or antisense strand of an HBB gene, the method comprising contacting the HBB gene with a base editor and a guide RNA bound to the base editor, wherein the guide RNA comprises a guide sequence that is complementary to a target nucleic acid sequence in the HBB gene.

### Claim at position 28

-145. (canceled)

### Claim 146

A method for deaminating an adenosine (A) nucleobase in a sense or antisense strand of an F8 gene, the method comprising contacting the F8 gene with a base editor and a guide RNA bound to the base editor, wherein the guide RNA comprises a guide sequence that is complementary to a target nucleic acid sequence in the F8 gene.

### Claim at position 30

-171. (canceled)

### Claim 172 (depends on 1)

The method of claim 1, wherein the base editor comprises a fusion protein comprising (i) a nucleic acid programmable DNA binding protein (napDNAbp) and (ii) an adenosine deaminase.

### Claim at position 32

-189. (canceled)

### Claim 190 (depends on 172)

The method of claim 172, wherein the adenosine deaminase comprises each of the W23R, H36L, P48A, R51L, L84F, A106V, D108N, H123Y, S146C, D147Y, R152P, E155V, I156F, and K157N mutations in SEQ ID NO: 1, or the corresponding mutations in another deaminase.

### Claim at position 34

-220. (canceled)

### Claim 221 (depends on 172)

The method of claim 172, wherein the fusion protein further comprises (iii) a guide RNA bound to the nucleic acid programmable DNA binding protein (napDNAbp), wherein the guide RNA (gRNA) comprises a guide sequence that is complementary to a target nucleic acid sequence in the promoter at least one of the HBG1 and HBG2 gene.

### Claim at position 36

-229. (canceled)

### Claim 230 (depends on 221)

The method of claim 221, wherein the guide sequence of the guide RNA comprises the nucleic acid sequence
(SEQ ID NO: 254)
5′-GACAGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 255)
5′-ACAGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 256)
5′-CAGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 257)
5′-AGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 258)
5′-GAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 259)
5′-AUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 260)
5′-AUGCAAAUAUCUGUCUGAAACGG-3′;
(SEQ ID NO: 261)
5′-GCAAAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 262)
5′-CAAAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 263)
5′-AAAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 264)
5′-AAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 265)
5′-AUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 266)
5′-UAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 267)
5′-AGAUAUUUGCAUUGAGAUAGUGU-3′;
(SEQ ID NO: 268)
5′-ACAGAUAUUUGCAUUGAGAUAGU-3′;
(SEQ ID NO: 269)
5′-GUGGGGAAGGGGCCCCCAAGAGG-3′;
(SEQ ID NO: 270)
5′-CUUGACCAAUAGCCUUGACAAGG-3′;
(SEQ ID NO: 271)
5′-CUUGUCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 272)
5′-UUGUCAAGGCUAUUGGUCAAGGCAAGG-3′ ;
(SEQ ID NO: 273)
5′-UGUCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 274)
5′-GUCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 275)
5′-UCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 276)
5′-CAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 277)
5′-UUGUCAAGGCUAUUGGUCAAGGC-3′;
(SEQ ID NO: 278)
5′-CUUGUCAAGGCUAUUGGUCAAGG-3′;
(SEQ ID NO: 279)
5′-UUGACCAAUAGCCUUGACAAGGC-3′;
or
(SEQ ID NO: 280)
5′-UAGCCUUGACAAGGCAAACUUGA-3′.

### Claim at position 38

-242. (canceled)

### Claim 243 (depends on 1)

The method of claim 1, wherein the method causes less than 1% indel formation.

### Claim 244 (depends on 1)

The method of claim 1, wherein the efficiency of deaminating an A nucleobase is at least 30%.

### Claim at position 41

-261. (canceled)

### Claim 262

A complex comprising (i) a fusion protein comprising (i) a nucleic acid programmable DNA binding protein (napDNAbp) and (ii) an adenosine deaminase, and a guide RNA, wherein the guide RNA comprises a guide sequence comprising the nucleic acid sequence
(SEQ ID NO: 254)
5′-GACAGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 255)
5′-ACAGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 256)
5′-CAGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 257)
5′-AGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 258)
5′-GAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 259)
5′-AUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 260)
5′-AUGCAAAUAUCUGUCUGAAACGG-3′;
(SEQ ID NO: 261)
5′-GCAAAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 262)
5′-CAAAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 263)
5′-AAAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 264)
5′-AAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 265)
5′-AUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 266)
5′-UAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 267)
5′-AGAUAUUUGCAUUGAGAUAGUGU-3′;
(SEQ ID NO: 268)
5′-ACAGAUAUUUGCAUUGAGAUAGU-3′;
(SEQ ID NO: 269)
5′-GUGGGGAAGGGGCCCCCAAGAGG-3′;
(SEQ ID NO: 270)
5′-CUUGACCAAUAGCCUUGACAAGG-3′;
(SEQ ID NO: 271)
5′-CUUGUCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 272)
5′-UUGUCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 273)
5′-UGUCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 274)
5′-GUCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 275)
5′-UCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 276)
5′-CAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 277)
5′-UUGUCAAGGCUAUUGGUCAAGGC-3′;
(SEQ ID NO: 278)
5′-CUUGUCAAGGCUAUUGGUCAAGG-3′;
(SEQ ID NO: 279)
5′-UUGACCAAUAGCCUUGACAAGGC-3′;
[[or]]
(SEQ ID NO: 280)
5′-UAGCCUUGACAAGGCAAACUUGA-3′;
(SEQ ID NO: 281)
5′-UUCUCCACAGGAGUCAGAUGCAC-3′;
(SEQ ID NO: 282)
5′-UCUCCACAGGAGUCAGAUGCACC-3′;
(SEQ ID NO: 283)
5′-UUCUCCACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 284)
5′-UCUCCACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 285)
5′-CUCCACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 286)
5′-UCCACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 287);
5′-CCACAGGAGUCAGAUGCACCAUGG-3′
(SEQ ID NO: 288)
5′-CACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 289)
5′-ACUUCUCCACAGGAGUCAGAUGC-3′;
(SEQ ID NO: 290)
5′-UCUCCACAGGAGUCAGAUGCACCAUGGU-3′;
(SEQ ID NO: 291)
5′-ACUCCUAAGGAGAAGUCUGCCGU-3′;
(SEQ ID NO: 292)
5′-UUGGUGGUAAGGCCCUGGGCAGG-3′;
(SEQ ID NO: 293)
5′-UGGUGGUAAGGCCCUGGGCAGGU-3′;
(SEQ ID NO: 294)
5′-UGGUAAGGCCCUGGGCAGGUUGG-3′;
(SEQ ID NO: 295)
5′-AGCAUUGUAUAUUCUCUGUGAGG-3′;
(SEQ ID NO: 296)
5′-AAAGCAUUGUAUAUUCUCUGUGA-3′.
(SEQ ID NO: 862)
5′-AUAUACGUACCAGGUGGAGCACCC-3′;
(SEQ ID NO: 863)
5′-UAUACGUACCAGGUGGAGCACCC-3′;
(SEQ ID NO: 864)
5′-AUACGUACCAGGUGGAGCACCC-3′;
(SEQ ID NO: 865)
5′-UACGUACCAGGUGGAGCACCC-3′;
(SEQ ID NO: 866)
5′-ACGUACCAGGUGGAGCACCC-3′;
(SEQ ID NO: 867)
5′-CGUACCAGGUGGAGCACCC-3′;
(SEQ ID NO: 868)
5′-GUACCAGGUGGAGCACCC-3′;
or
(SEQ ID NO: 869)
5′-UACCAGGUGGAGCACCC-3′.

### Claim at position 43

-264. (canceled)

### Claim 265

A single guide RNA (sgRNA) comprising the nucleic acid sequence
(SEQ ID NO: 846)
5′-UCAUGUGGGGAAGGGGCCCCCAAG-3′;
(SEQ ID NO: 847)
5′-CAUGUGGGGAAGGGGCCCCCAAG-3′;
(SEQ ID NO: 848)
5′-AUGUGGGGAAGGGGCCCCCAAG-3′;
(SEQ ID NO: 849)
5′-UGUGGGGAAGGGGCCCCCAAG-3′.
(SEQ ID NO: 850)
5′-GUGGGGAAGGGGCCCCCAAG-3′;
(SEQ ID NO: 851)
5′-UGGGGAAGGGGCCCCCAAG-3′;
(SEQ ID NO: 852)
5′-GGGGAAGGGGCCCCCAAG-3′;
(SEQ ID NO: 853)
5′-GGGAAGGGGCCCCCAAG-3′;
(SEQ ID NO: 862)
5′-AUAUACGUACCAGGUGGAGCACCC-3′;
(SEQ ID NO: 863)
5′-UAUACGUACCAGGUGGAGCACCC-3′;
(SEQ ID NO: 864)
5′-AUACGUACCAGGUGGAGCACCC-3′;
(SEQ ID NO: 865)
5′-UACGUACCAGGUGGAGCACCC-3′;
(SEQ ID NO: 866)
5′-ACGUACCAGGUGGAGCACCC-3′;
(SEQ ID NO: 867)
5′-CGUACCAGGUGGAGCACCC-3′;
(SEQ ID NO: 868)
5′-GUACCAGGUGGAGCACCC-3′;
(SEQ ID NO: 869)
5′-UACCAGGUGGAGCACCC-3′;
(SEQ ID NO: 254)
5′-GACAGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 255)
5′-ACAGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 256)
5′-CAGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 257)
5′-AGAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 258)
5′-GAUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 259)
5′-AUAUUUGCAUUGAGAUAGUGUGG-3′;
(SEQ ID NO: 260)
5′-AUGCAAAUAUCUGUCUGAAACGG-3′;
(SEQ ID NO: 261)
5′-GCAAAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 262)
5′-CAAAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 263)
5′-AAAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 264)
5′-AAUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 265)
5′-AUAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 266)
5′-UAUCUGUCUGAAACGGUCCCUGG-3′;
(SEQ ID NO: 267)
5′-AGAUAUUUGCAUUGAGAUAGUGU-3′;
(SEQ ID NO: 268)
5′-ACAGAUAUUUGCAUUGAGAUAGU-3′;
(SEQ ID NO: 269)
5′-GUGGGGAAGGGGCCCCCAAGAGG-3′;
(SEQ ID NO: 270)
5′-CUUGACCAAUAGCCUUGACAAGG-3′;
(SEQ ID NO: 271)
5′-CUUGUCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 272)
5′-UUGUCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 273)
5′-UGUCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 274)
5′-GUCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 275)
5′-UCAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 276)
5′-CAAGGCUAUUGGUCAAGGCAAGG-3′;
(SEQ ID NO: 277)
5′-UUGUCAAGGCUAUUGGUCAAGGC-3′;
(SEQ ID NO: 278)
5′-CUUGUCAAGGCUAUUGGUCAAGG-3′;
(SEQ ID NO: 279)
5′-UUGACCAAUAGCCUUGACAAGGC-3′;
(SEQ ID NO: 280)
5′-UAGCCUUGACAAGGCAAACUUGA-3′;
(SEQ ID NO: 281)
5′-UUCUCCACAGGAGUCAGAUGCAC-3′;
(SEQ ID NO: 282)
5′-UCUCCACAGGAGUCAGAUGCACC-3′;
(SEQ ID NO: 283)
5′-UUCUCCACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 284)
5′-UCUCCACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 285)
5′-CUCCACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 286)
5′-UCCACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 287)
5′-CCACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 288)
5′-CACAGGAGUCAGAUGCACCAUGG-3′;
(SEQ ID NO: 289)
5′-ACUUCUCCACAGGAGUCAGAUGC-3′;
(SEQ ID NO: 290)
5′-UCUCCACAGGAGUCAGAUGCACCAUGGU-3′;
(SEQ ID NO: 291)
5′-ACUCCUAAGGAGAAGUCUGCCGU-3′;
(SEQ ID NO: 292)
5′-UUGGUGGUAAGGCCCUGGGCAGG-3′;
(SEQ ID NO: 293)
5′-UGGUGGUAAGGCCCUGGGCAGGU-3′;
[[or]]
(SEQ ID NO: 294)
5′-UGGUAAGGCCCUGGGCAGGUUGG-3′;
(SEQ ID NO: 295)
5′-AGCAUUGUAUAUUCUCUGUGAGG-3′;
or
(SEQ ID NO: 296)
5′-AAAGCAUUGUAUAUUCUCUGUGA-3′.

### Claim at position 45

-267. (canceled)

### Claim 268 (depends on 265)

A vector comprising a nucleic acid encoding any single guide RNA of claim 265, wherein the vector comprises a heterologous promoter that drives expression of the guide RNA.

### Claim 269

(canceled)

### Claim 270 (depends on 262)

A pharmaceutical composition comprising the complex of claim 262.

### Claim at position 49

-272. (canceled)
